TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00836875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension.
Study: NCT04981379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo \[Hydroxychloroquine (200 mg)\], as two tablets per day for 5-day interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir + Hydroxychloroquine
Description: Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[Favipiravir (1600 mg)\], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.
Study: NCT00786318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: ziprasidone 20mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Haldol 5mg/ Ativan 2mg IM
Study: NCT03282890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHRP-BB
Description: The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
Study: NCT02548208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum focused extracorporeal shockwave
Description: the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham shock wave
Description: Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
Study: NCT01111617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI feedback
Description: Patients receive real-time fMRI biofeedback to modulate pain
Study: NCT02386982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Study: NCT04089761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio
Description: Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Study: NCT03631342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCV20
Description: controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCV40
Description: volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV
Description: controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
Study: NCT01855594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 250 mg/tablet, 6 weeks course of oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet, 6 week course of oral administration
Study: NCT03631342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV+Tins
Description: controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV
Description: ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
Study: NCT00704366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral, tablet, once daily, dose will be variable
Study: NCT01504126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Undergo standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT01980186

Intervention type: DEVICE
Intervention: TUS transcranial 2D ultrasound
Study: NCT00895115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given once daily
Study: NCT03456986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH neurotraining
Description: Tunes up the center of the motion discrimination (dorsal stream) working range

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation Discrimination
Description: Tunes up the ventral stream most sensitive to high contrast and colored patterns.
Study: NCT00582634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
Study: NCT00389168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Titrated to 300 mg od, 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Titrated to 100 mg od, 48 weeks.
Study: NCT02492009

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Decision Aid
Description: The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.
Study: NCT03761979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strontium L-lactate
Description: The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
Study: NCT02928328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA oral solution
Description: Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
Study: NCT00981565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open carpal tunnel release
Description: surgery to release the carpal tunnel
Study: NCT02928328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular GABA
Description: The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain modulation
Description: The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
Study: NCT04605757

Intervention type: OTHER
Intervention: Clinical, functional and radiological lung involvement evolution
Description: Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
Study: NCT04990986

Intervention type: OTHER
Group type: OTHER
Intervention: Complex intervention
Description: Will be co-developed during the study.
Study: NCT00945503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 is a GT1 recepor antagonist
Study: NCT04063033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron - Sodium Ferric Gluconate Complex
Description: IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
Study: NCT02485912

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z
Description: This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO Z
Description: This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z
Description: This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-EBO Z
Description: This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
Study: NCT00981565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Night-cast
Description: individual night time splinting
Study: NCT00790972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinofresh
Description: two sprays in each nostril three times daily for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two sprays in each nostril three times daily for one week
Study: NCT03804060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermogard XP3
Description: Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recanalization only
Description: Standard of Care for recanalization
Study: NCT01473537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium lactate solution
Description: Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium lactate solution
Description: Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: calcium lactate solution
Description: Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
Study: NCT00566397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700
Description: 15 mg for 6 days followed by daily dosing of 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700
Description: 60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04703647

Intervention type: OTHER
Intervention: Administration of questionnaires for prospective group
Description: Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .

Intervention type: OTHER
Intervention: Blood samples for prospective group
Description: Blood samples at T0,T1,T2 and T3.

Intervention type: OTHER
Intervention: Blood samples for control group
Description: Blood samples just one time
Study: NCT02575807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: via IV infusion
Study: NCT03761979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strontium L-lactate
Description: The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strontium L-lactate
Description: The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
Study: NCT02289885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoScape
Description: Ultrasonography device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoScape
Description: Ultrasonography device
Study: NCT02465606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Description: Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Description: Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
Study: NCT04269811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu-Bu-Mel
Description: 5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
Study: NCT01441258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills (DBT-S) Groups
Description: The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait List-Treatment as Usual
Description: Participants will be seen by their standard treaters for 18 weeks as usual.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention-treatment as usual
Description: Participants will receive the intervention after 18 weeks in the treatment as usual group.
Study: NCT01497678

Intervention type: DEVICE
Group type: OTHER
Intervention: Extracellular Matrix
Description: Extracellular Matrix
Study: NCT02076802

Intervention type: BEHAVIORAL
Intervention: physical exercises
Study: NCT06415071

Intervention type: OTHER
Intervention: No intervention
Description: Exposures of interest would be clearly defined according to a specific research question and identified from the database
Study: NCT01786551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50 mg daily for 14 days
Study: NCT00692757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid
Description: Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodopovidone
Description: Iodopovidone
Study: NCT02674178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invitro fertilization
Description: All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval
Study: NCT02575807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: PO BID
Study: NCT01090726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz videolaryngoscope
Description: Storz videolaryngoscope being used for the actual intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Airtraq being used for the actual intubation
Study: NCT01705288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
Study: NCT00895115

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: No supplementation
Study: NCT03392220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Neck Dissection
Description: patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
Study: NCT01705288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous narcotics
Description: given for pain management after surgery per physician orders

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard anesthesia
Description: inhalant or intravenous during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: given by spinal or epidural infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs
Description: given for pain management after surgery
Study: NCT02575807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: PO BID